Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep:61:101114.
doi: 10.1016/j.blre.2023.101114. Epub 2023 Jul 13.

Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review

Allison Mo  1 , Matthew Poynton  2 , Erica Wood  3 , Jake Shortt  4 , Susan J Brunskill  5 , Carolyn Doree  5 , Josie Sandercock  5 , Nicholas Saadah  6 , Edwin Luk  7 , Simon J Stanworth  8 , Zoe McQuilten  9
Affiliations
Free article

Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review

Allison Mo et al. Blood Rev. 2023 Sep.
Free article

Abstract

Anemia is common in Myelodysplastic Syndromes (MDS). Different anemia treatments have been tested in clinical studies, but the full impact on patients' health-related quality of life (HRQoL) and physical function is unknown. The main aim of this review was to assess whether improvements in anemia are associated with changes in HRQoL/physical function. Twenty-six full-text publications were identified, enrolling 2211 patients: nine randomized trials (RCTs), fourteen non-randomized studies of interventions and three cross-sectional studies. Interventions included: growth factors/erythropoiesis-stimulating agents (n = 14), red cell transfusion (n = 9), erythroid maturation agents (n = 1), or a combination (n = 2). Five RCTs reported no changes in HRQoL despite erythroid response to the intervention, raising the question of whether anemia treatment alone can effectively improve HRQoL. Many studies were considered at high risk of bias for assessing HRQoL. There is a pressing need for future clinical trials to better define the nature of the relationship between anemia and HRQoL/functional outcomes.

Keywords: Anemia; Myelodysplastic syndrome; Physical function; Quality of life; Transfusion medicine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest AM is supported by scholarship funding from National Health and Medical Research Council (NHMRC), Haematology Society of Australia and New Zealand (HSANZ), National Blood Authority (NBA) and Monash University. This work is also supported by the NHMRC funded Blood Syneergy program. MP is supported by the National Institute for Health Research (NIHR). ZM and JS are supported by Australian NHMRC Emerging Leadership Fellowships. EW is supported by NHMRC Leadership Fellowship. ZM and EW have also received support for other research work (not related to this submitted work) from Abbvie, Amgen, Antegene, AstraZeneca, Beigene, Bristol Myers-Squibb/Celgene, CSL Behring, Dova/Sobi Pharmaceuticals, Janssen, Novartis, Roche, Sanofi, Takeda. JS has received research funding (not related to this submitted work) from Amgen, Bristol Myers Squibb, Astex; and is on advisory boards for Novartis, Mundipharma, Otsuka, Astellas, Bristol Myers Squibb, Pfizer and on the speakers bureau for Mundipharma and Novartis. SS, JSa, CD, SB, EL, NS have no disclosures.

Publication types